Naropin is owned by Fresenius Kabi Usa.
Naropin contains Ropivacaine Hydrochloride.
Naropin has a total of 4 drug patents out of which 0 drug patents have expired.
Naropin was authorised for market use on 24 September, 1996.
Naropin is available in solution;injection dosage forms.
The generics of Naropin are possible to be released after 28 November, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8118802||FRESENIUS KABI USA||Connector for packaging containing medical fluids and packaging for medical fluids|| |
(3 months from now)
|US8162915||FRESENIUS KABI USA||Connector for packings containing medical liquids, and corresponding packing for medical liquids|| |
(1 year, 3 months from now)
|US7828787||FRESENIUS KABI USA||Connector for packaging containing medical fluids and packaging for medical fluids|| |
(2 years from now)
|US7857802||FRESENIUS KABI USA||Connector for medical liquid-containing packages and medical liquid-containing packages|| |
(3 years from now)
Market Authorisation Date: 24 September, 1996
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic